This study aimed to evaluate Fibroindex as simple noninvasive modelconsisting of routine laboratory tests derived from the platelet count,AST, and gammaglobulin measurements as predictor of clinicallysignificant fibrosis in 33 patients with chronic HCV infection, andcomparing its diagnostic performance to aminotransferase to platelet ratioindex (APRI). The study revealed a significant positive correlationbetween Fibroindex and stage of fibrosis. The areas under the ROCcurves for the Fibroindex were 0.962, 0.930 for predicting significantfibrosis (F2-F3) and cirrhosis (F4) respectively, better than theaminotransferase to platelet ratio index (APRI). Using the best cutoffvalues, significant fibrosis was diagnosed with high positive predictivevalue. Fibroindex had better sensitivity, specificity, positive and negativepredictive values when compared with APRI. The study revealed thatFibroindex is a reliable noninvasive test in predicting HCV relatedfibrosis compared to liver biopsy being the gold standard for diagnosis ofhepatic fibrosis.